Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
基本信息
- 批准号:10018469
- 负责人:
- 金额:$ 49.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:16S ribosomal RNA sequencingAgeAntitumor ResponseB-LymphocytesBacteriaBacteroidesBifidobacteriumBindingBioinformaticsBiometryCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCTLA4 blockadeCXCR6 geneCell MaturationCell physiologyCellsCessation of lifeClinicalClinical TrialsCorrelative StudyCytotoxic T-LymphocytesDendritic CellsDietEtiologyEvaluationExhibitsExperimental NeoplasmsFailureFecesFrequenciesFunding AgencyGerm-FreeHumanImmuneImmune responseImmunologicsImmunosuppressionIn VitroInnate Immune ResponseIntestinesInvestigationLigandsLiverMetagenomicsMetastatic Neoplasm to the LiverModelingMonoclonal AntibodiesMusNon-Small-Cell Lung CarcinomaOutcomePD-1 blockadePD-1/PD-L1PatientsPharmaceutical PreparationsPlayPublishingRNARegulatory T-LymphocyteRenal carcinomaReportingResearch PersonnelResistanceRoleSystems BiologyT cell responseT-LymphocyteT-cell inflamedTestingTimeTumor AntigensTumor-Infiltrating LymphocytesUnited States National Institutes of Healthadaptive immune responseanti-CTLA4anti-PD-1anti-PD1 antibodiesanti-PD1 therapyantitumor effectbasecancer immunotherapycohortcommensal bacteriadysbiosiseffector T cellexhaustexperimental studyfecal transplantationgut microbiomegut microbiotaimmune checkpoint blockadeinter-individual variationmelanomamicrobiota profilesmouse modelnovelprogrammed cell death ligand 1programmed cell death protein 1receptorreconstitutionresponsesextumortumor growthtumor immunology
项目摘要
Abstract
There is ample evidence that melanoma patients (MPs) develop immune responses directed against tumor-
associated antigens. However, high frequencies of tumor antigen-specific cytotoxic T-lymphocytes (CTL) often
fail to induce tumor rejection. Among the numerous mechanisms of tumor-induced immunosuppression that
contribute to the resistance of tumors to CTL responses, it is now well established that inhibitory receptors like
PD1 play a critical role in dampening T cell responses to tumors. As a result, therapy with blocking anti-PD1
monoclonal antibodies has become one of the most potent therapies of melanoma, providing prolonged clinical
benefits to 30-40% advanced MPs. There is strong evidence that pre-existing CD8+ tumor-infiltrating T cells
correlate with clinical antitumor response to PD1 blockade. However, not all T cell-inflamed tumors respond to
PD1 blockade and not all melanomas are inflamed. Hence, the mechanisms supporting response or resistance
to PD1 blockade remain to be precisely determined. Two studies have shown the role of the gut microbiome in
regulating clinical responses to CTLA4 and PD1 blockade in murine melanoma model. In addition, two studies
in NSCLCs and renal cancers (RC), and melanoma patients (MPs), respectively, have shown that the
presence of certain commensals correlated with better clinical outcome upon PD1 blockade. Fecal microbiota
transplant (FMT) from PD1 responders (PD1Rs) in melanoma-bearing GF mice reduced significantly tumor
growth as compared to FMT from PD1 non-responders (PD1NRs). We have observed the increased
abundance of certain bacterial commensals in stools of PD1Rs as compared to PD1NRs, albeit significantly
different from the ones recently published. The striking differences between our findings and the recent
published study are not totally surprising when one considers the greater complexity and inter-individual
variability of the human gut microbiota upon many host-dependent variables. It is therefore critically important
to expand these studies in a larger number of MPs using state-of-the-art omic approach (metagenomics) and
Systems Biology to evaluate the direct causality between commensal bacteria and clinical outcome. Here, we
propose to test whether the gut microbiome modulates immune and clinical responses to PD1 blockade in the
context a novel clinical trial with FMT obtained from PD1Rs combined with PD1 blockade in PD1NRs. This
project will test the novel hypotheses that: 1) PD1Rs exhibit distinct gut microbiota profiles in terms of diversity,
abundance and dynamics over time compared with PD1NRs; 2) the administration of single PD1R-derived
FMT to a PD1NRs together with PD1 blockade promotes clinical antitumor response; and 3) the occurrence of
clinical responses in MPs treated with FMT and PD1 blockade correlates with T cell responses to melanoma.
This proposal will take advantage of the well-established and cross-disciplinary expertise of the investigators in
melanoma, human cancer immunology, gut microbiome and metaomics, biostatistics, and systems biology.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HASSANE M ZAROUR其他文献
HASSANE M ZAROUR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HASSANE M ZAROUR', 18)}}的其他基金
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法
- 批准号:
10683757 - 财政年份:2021
- 资助金额:
$ 49.85万 - 项目类别:
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法
- 批准号:
10469636 - 财政年份:2021
- 资助金额:
$ 49.85万 - 项目类别:
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法
- 批准号:
10270232 - 财政年份:2021
- 资助金额:
$ 49.85万 - 项目类别:
Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
- 批准号:
10441408 - 财政年份:2018
- 资助金额:
$ 49.85万 - 项目类别:
Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
- 批准号:
10196995 - 财政年份:2018
- 资助金额:
$ 49.85万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 49.85万 - 项目类别:
Research Grant